THERAPEUTIC AREA
savePulmonology
Diseases of the lungs and respiratory tract.
also known as: respiratory, lung, pulmonary
🐶 often sniffed alongside
top 8- tagOncology207 co-mentions · 51 sources
- tagNSCLC108 co-mentions · 47 sources
- tagAdCom58 co-mentions · 53 sources
- tagRecall49 co-mentions · 33 sources
- tag510(k) Clearance35 co-mentions · 30 sources
- tagCardiology25 co-mentions · 17 sources
- tagPMA Approval23 co-mentions · 23 sources
- tagInfectious Disease21 co-mentions · 20 sources
drugs
396
catalysts
22
news
2,254
companies
278
Top drugs
view all →Marketed
CLEOCIN
$PFE · 127 catalysts
Marketedclindamycin hydrochloride
Bacterial Pneumonia
90 catalysts
MarketedNALBUPHINE HYDROCHLORIDE
Pain
84 catalysts
MarketedDOXYCYCLINE HYCLATE
$AMRX · 49 catalysts
Marketedmethylprednisolone sodium succinate
Drug Hypersensitivity Reactions
48 catalysts
MarketedMETHYLPREDNISOLONE ACETATE
Giant Cell Arteritis (Temporal Arteritis/Cranial Arteriti…
41 catalysts
MarketedMETRONIDAZOLE
Bacterial Endocarditis
36 catalysts
MarketedMEDROL
$PFE · 34 catalysts
🐶 Top companies
view all →Recent catalysts
view all →Apr 30, 2026
phase 2 completion
Huadong Hospital Affiliated to Fudan University — lidocaine (Phase II Trial Completion)
LIDOCAINE
→
Apr 30, 2026
phase 2 completion
$AZN178.84-1.88%
AstraZeneca Plc — tozorakimab (Phase II Trial Completion)
tozorakimab
→
Apr 30, 2026
phase 2 completion
$MRK137.78-3.90%
Merck & Co Inc — tulisokibart (Phase II Trial Completion)
tulisokibart
→
Apr 30, 2026
phase 2 completion
Brigham and Women's Hospital — dupilumab (Phase II Trial Completion)
dupilumab
→
Apr 30, 2026
phase 1 2 completion
Wuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)
M-701
→
Apr 30, 2026
phase 1 completion
Beijing Minhai Biotechnology Co Ltd — pneumococcal (20-valent) vaccine (Phase I Trial Completion)
pneumococcal (20-valent) vaccine
→
Apr 30, 2026
phase 0 trial completion
Civil Aviation General Hospital — dexmedetomidine (Phase 0 Trial Completion)
dexmedetomidine
→
Apr 30, 2026
constraining patent expiry europe
$CPIX6.5700+13.28%
Cumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))
telavancin hydrochloride
→
Apr 29, 2026
phase 3 initiation
Chia Tai Tianqing Pharmaceutical Group Co Ltd — TQH-2722 (Phase III Trial Initiation)
TQH-2722
→
Apr 29, 2026
phase 2 initiation
Shenzhen Resproly Biopharmaceutical Co Ltd — RSN-0402 (Phase II Trial Initiation)
RSN-0402
→
Recent news
view all →- STAT+: Influential preventive services panel to meet for first time in more than a yearstat · 7h ago
- Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concernsbiospace · 13h ago
- STAT+: FDA discloses reasons for rejecting Summit drugstat · 13h ago
- STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and morestat · 14h ago
- FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSKbiopharma dive · 14h ago
- GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buybiospace · 15h ago
- Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safetybiospace · 15h ago
- Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlightbiospace · 17h ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that